The NFKBIA Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the NFKBIA gene in the Raji B lymphocyte model. NFKBIA encodes I??B??, the primary cytoplasmic inhibitor of NF-??B transcription factors. By generating a heterogeneous pool of edited cells, this polyclonal format enables the study of functional gene loss within a bulk population, minimizing clonal selection artifacts and approximating natural genetic variability. The product is provided as a ready-to-use, cryopreserved cell stock suitable for expansion and downstream molecular, biochemical, and pharmacological analyses.
The host cell line, Raji, is an Epstein-Barr virus (EBV)-positive Burkitt lymphoma B-cell line derived from a human male. These cells maintain key B-lymphocyte characteristics, including surface immunoglobulin expression, antigen presentation capacity, and the ability to support latent EBV gene expression programs. Raji cells are widely employed in immunology and cancer research owing to their constitutive activation of survival signaling networks, including NF-??B, driven in part by the EBV oncoprotein LMP1, which mimics CD40 receptor signaling. This background provides a physiologically relevant context for examining the consequences of NFKBIA loss in a malignant B-cell environment.
NFKBIA encodes I??B??, which normally sequesters NF-??B dimers??predominantly RELA:NFKB1??in the cytoplasm under resting conditions. Upon stimulation by upstream activators such as tumor necrosis factor alpha (TNF??), interleukin-1 beta (IL-1??), lipopolysaccharide (LPS), or B-cell receptor (BCR) engagement, the I??B kinase (IKK) complex, comprising IKK?? (IKBKB) and IKK?? (IKBKG), phosphorylates I??B??, marking it for ubiquitination by beta-TrCP E3 ligase and subsequent proteasomal degradation. This releases NF-??B to translocate into the nucleus and activate a broad transcriptional program. Knockout of NFKBIA removes this regulatory checkpoint, leading to constitutive nuclear localization and transcriptional activity of NF-??B, which drives enhanced expression of pro-inflammatory cytokines (IL-6, TNF??), anti-apoptotic factors (BCL2L1, XIAP), proliferation regulators (MYC, CCND1), and B-cell differentiation factors (IRF4, AICDA).
In the Raji Burkitt lymphoma context, the disappearance of I??B?? exacerbates the already dysregulated NF-??B signaling characteristic of EBV-driven B-cell malignancies. This model recapitulates a state of constitutive pathway activation that mirrors pathologic conditions observed in aggressive lymphomas and inflammatory disorders. The absence of I??B??-mediated feedback inhibition allows researchers to dissect the direct transcriptional outputs of unrestrained NF-??B activity and to investigate mechanisms of apoptosis resistance, uncontrolled proliferation, and altered differentiation programs intrinsic to B-cell oncogenesis.
This knockout cell population is suited for a wide array of functional and pharmacological investigations, including high-throughput screening of NF-??B pathway inhibitors, evaluation of drug candidates (e.g., BTK inhibitors), and mechanistic studies of B-cell activation and survival. Representative assays encompass western blotting for I??B?? and phospho-p65, NF-??B luciferase reporter assays, RT-qPCR quantification of target transcripts (IL6, BCL2L1), Annexin V apoptosis detection, flow cytometric profiling of B-cell markers, phospho-IKK immunodetection, and cell proliferation analyses. Researchers can employ this tool for comparative gene expression, protein interaction, and drug sensitivity profiling to advance understanding of NF-??B-driven pathologies. For further technical details or customized support, please contact Ascent Research.
